Leuproreline Zentiva (Leuprorelin Acetate)

Leuprorelin acetate is a synthetic analogue of the natural hormone GnRH. It binds to GnRH receptors in the pituitary gland, initially causing a brief surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). Continued exposure leads to receptor down‑regulation, which markedly reduces LH and FSH secretion and consequently lowers circulating testosterone or estrogen levels.

The specific dose and dosing interval of Leuproreline Zentiva are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, weight, and response to therapy. Dosing regimens may vary from monthly to quarterly injections, and the prescriber will tailor the schedule to achieve optimal hormonal suppression while monitoring safety.

Leuprorelin acetate is contraindicated in pregnancy because it can interfere with normal fetal hormone development. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose. The safety of the drug during lactation has not been established, and breastfeeding is generally not recommended while on therapy.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling if needed), and assists with any required import documentation.

Leuproreline Zentiva is chemically identical to other leuprorelin products and shares the same mechanism of action as alternative GnRH agonists such as goserelin or triptorelin. Differences may lie in formulation, dosing frequency, and packaging. Clinical efficacy and safety are comparable when used at equivalent doses, but individual patient factors and convenience of administration often guide the choice of product.

Leuproreline Zentiva should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and direct sunlight. Do not freeze the product. If the medication is supplied as a pre‑filled syringe, keep the syringe upright and avoid shaking to maintain formulation integrity.

Leuproreline Zentiva is given by subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed by a healthcare professional using aseptic technique. The volume and concentration depend on the prescribed dose, and the injection site should be rotated to minimize local irritation.

Serious adverse events, although uncommon, include cardiovascular complications such as myocardial infarction or stroke, severe allergic reactions (anaphylaxis), significant bone mineral density loss leading to osteoporosis, and rare cases of pituitary apoplexy. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if any serious reaction occurs.

Leuproreline Zentiva is contraindicated in individuals with known hypersensitivity to leuprorelin acetate or any excipients in the formulation. It should also be avoided in patients with severe uncontrolled cardiovascular disease, active bone metastases, or those who are pregnant. Clinicians must assess each patient’s medical history before initiating therapy.